Showing 1 - 10 results of 10 for search '"recombinant antibodies"', query time: 0.04s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71 by Rosalba Parenti, Lucia Salvatorelli, Gaetano Magro

    Published 2014-01-01
    “…In this regard, new therapeutic approaches based on the use of monoclonal or recombinant antibodies, or transferrin-gallium-TfR1/CD71 molecular complexes, or lastly small interfering RNAs (siRNAs) are proposed.…”
    Get full text
    Article
  7. 7

    Comparative Glycopeptide Analysis for Protein Glycosylation by Liquid Chromatography and Tandem Mass Spectrometry: Variation in Glycosylation Patterns of Site-Directed Mutagenized... by Young Hye Hahm, Sung Ho Hahm, Hyoun Young Jo, Yeong Hee Ahn

    Published 2018-01-01
    “…In this study, glycopeptide mapping of a reference and biosimilar recombinant antibodies (rAbs) was performed using liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) and an automated Glycoproteome Analyzer (GPA) algorithm. …”
    Get full text
    Article
  8. 8

    The effect of differences in the third domain of the glycoprotein E of tick-borne encephalitis virus of the Far Eastern, Siberian and European subtypes on the binding of recombinan... by I. K. Baykov, A. L. Matveev, L. A. Emelianova, G. B. Kaverina, S. E. Tkachev, N. V. Tikunova

    Published 2019-05-01
    “…Currently, a therapeutic drug based on recombinant antibodies for the prevention and treatment of tick-borne encephalitis virus (TBEV) is developed in ICBFM SB RAS, and the chimeric antibody ch14D5 is considered as one of the key components of this drug. …”
    Get full text
    Article
  9. 9

    DNA-loaded targeted nanoparticles as a safe platform to produce exogenous proteins in tumor B cells by Maria Cristina Grimaldi, Sara Bozzer, Dick J. Sjöström, Dick J. Sjöström, Linnea I. Andersson, Tom Eirik Mollnes, Tom Eirik Mollnes, Per H. Nilsson, Per H. Nilsson, Luca De Maso, Federico Riccardi, Michele Dal Bo, Daniele Sblattero, Paolo Macor

    Published 2025-01-01
    “…However, the nanoplatform must guarantee both the local production of the protein and the safety of the treatment to allow an effective therapy with reduced systemic toxicity.MethodsIn order to ensure a selective delivery of nucleic acids, we developed poly(lactic-co-glycolic acid) (PLGA)-poly(vinyl alcohol) (PVA) NPs loaded with an Enhanced Green Fluorescent Protein (EGFP)-coding plasmid and covalently coated with antiCD19 recombinant antibody as a targeting mechanism. To assess the functionality of the NPs, physicochemical characterization, safety tests, and transfection assay were employed to evaluate the NPs’ behavior in vitro and in vivo, in a human/zebrafish lymphoma xenograft model.ResultsThe results demonstrated that the PLGA-PVA nanoplatform was capable of efficiently encapsulating and releasing the payload. …”
    Get full text
    Article
  10. 10

    Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity by Congcong Zhang, Anja Waldmann, Winfried S Wels, Jasmin Röder, Anne Scherer, Malena Bodden, Jordi Pfeifer Serrahima, Anita Bhatti, Nina Müller, Pranav Oberoi

    Published 2021-10-01
    “…However, shedding or downregulation of NKG2D ligands (NKG2DL) can prevent NKG2D activation, resulting in escape of cancer cells from NKG2D-dependent immune surveillance.Methods To enable tumor-specific targeting of NKG2D-expressing effector cells independent of membrane-anchored NKG2DLs, we generated a homodimeric recombinant antibody which harbors an N-terminal single-chain fragment variable (scFv) antibody domain for binding to NKG2D, linked via a human IgG4 Fc region to a second C-terminal scFv antibody domain for recognition of the tumor-associated antigen ErbB2 (HER2). …”
    Get full text
    Article